Paul Hastings Advises Redmile on Series A Fundraising Round for One Biosciences
Paul Hastings LLP advised Redmile on the Series A fundraising round for One Biosciences, a precision oncology biotechnology company pioneering clinical-grade single-cell tumor transcriptomic profiling.
The financing will enable One Biosciences to accelerate the development of its platform to make precision medicine a clinical reality and will support the establishment of strategic partnerships with pharmaceutical and biotech groups seeking to integrate One Biosciences' proprietary single-cell offering, OneCure, into their drug development programs and clinical trials.
Private Equity partner Sébastien Crepy led the Paul Hastings team, which also included partner Bruno Leroy, of counsel Damien Fénard and associates Amaury Steinlin and Victoire Roussel.
With widely recognized elite teams across 18 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world's leading investment banks, asset managers and corporations.